(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 August 2003 (14.08.2003)

PCT

(10) International Publication Number
WO 03/066097 A2

(51) International Patent Classification[7]: A61K 39/395

(21) International Application Number: PCT/EP03/01229

(22) International Filing Date: 7 February 2003 (07.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

02075544.3	8 February 2002 (08.02.2002)	EP
02077742.1	9 July 2002 (09.07.2002)	EP
03100148.0	24 January 2003 (24.01.2003)	EP

(71) Applicants *(for all designated States except US)*: **VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW** [BE/BE]; Rijvisschestraat 120, B-9052 Zwijnaarde (BE). **D. COLLEN RESEARCH FOUNDATION VZW** [BE/BE]; Onderwijs & Navorsing, Campus Gasthuisberg, K.U. Leuven, Herestraat 49, B-3000 Leuven (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CARMELIET, Peter** [BE/BE]; Sappelenbos 10, B-3052 Blanden (BE). **MOONS, Lieve** [BE/BE]; Beningstraat 25, B-2230 Herselt (BE).

(74) Agent: **BRANTS, Johan, Philippe, Emile**; De Clercq, Brants & Partners cv, E. Gevaertdreef 10a, B-9830 Sint-Martens-Latem (BE).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/066097 A2

(54) Title: A NOVEL TARGET TO INHIBIT ANGIOGENESIS

(57) Abstract: The invention relates to the field of angiogenesis. In particular the invention relates to the use of molecules binding to prominin-1 that can be used for the manufacture of a medicament to prevent pathological angiogenesis.

A novel target to inhibit angiogenesis

Field of the invention

The invention relates to the field of angiogenesis. In particular the invention relates to the use of molecules binding to prominin-1 that can be used for the manufacture of a medicament to prevent pathological angiogenesis.

Background of the invention

Prominin-1 (PROM-1), also called AC133 or recently designed CD133 (National Center for Biotechnology, 2000), is a rather novel human hematopoietic stem cell antigen [1] of unknown physiological or pathological function. Prominin-1-antigen was first detected on $CD34^{bright}$ hematopoietic stem cells [2] and has since been widely used to facilitate the analysis and isolation of hematopoietic and primitive cells [3-5]. Only few prominin-1^+ cells do not coexpress CD34: these cells are very small and define a population of unknown delineation [6]. In acute myeloid leukemias, PROM-1 expression is often but not always associated with CD34 expression [7,8]. Prominin-1 is also found on acute lymphoid leukemia blasts and on a subset of $CD34^+$ B-cell precursors [9]. Flow cytometry analyses of a wide panel of human cell lines showed that only retinoblastoma and teratocarcinoma cell lines express prominin-1[10]. More recently, it was shown that endothelial progenitor cells co-express PROM-1 antigen and the endothelial cell-specific receptor kinase-inert domain-containing acceptor (KDR) in subpopulations of $CD34^+$ cells derived from fetal liver, bone marrow, cord blood and peripheral blood [11,12]. Recently, human central nervous system stem cells were also reported to express prominin-1-antigen [13]. A characteristic feature of this protein is its rapid down-regulation during cell differentiation [12,14], which makes it a unique cell surface marker for the identification and isolation of stem cells and progenitor cells. Human PROM-1 antigen is a glycoprotein of 120 KD and contains an extracellular N- terminus, two extracellular loops, five transmembrane domains, two small cysteine-rich cytoplasmic loops and a cytoplasmic C terminus [1]. Recently a novel isoform of human PROM-1 with a 27 basepair deletion has been described [15]. A structural and sequence-related protein, was identified as the mouse orthologue of human PROM-1 [14]. The 5-transmembrane structure appears phylogenetically conserved from mammals to zebrafish and in fruit flies and nematodes [16,17]. Murine prominin-1, which has a 65% amino acid homology

BESTÄTIGUNGSKOPIE

with human PROM-1 also exists in two isoforms. The short human and murine prominin isoform both encode proteins that lack a 9-amino acid segment at the same location in the N-terminal extracellular region just proximal to the first transmembrane domain [15,18,19]. Although human PROM-1 has been used as a cell surface marker to identify and isolate certain stem cell and progenitor cell populations, the molecular mechanism of how this protein functions remain unclear. The possible role of PROM-1 in hematopoiesis and vasculogenesis in the developing embryo and, after birth, in angiogenesis, postnatal vasculogenesis and hematopoietic stem cell trafficking, remains largely unknown. To study in detail the *in vivo* role of PROM-1 in the present invention PROM-1 deficient mice were generated. It was surprisingly found that PROM-1 has a key role in pathological angiogenesis and that inhibitors of PROM-1 can be used in therapeutic strategies to inhibit blood vessel formation in various pathological disorders.

Aims and detailed description of the invention

The "hemangioblast" is a putative progenitor cell that has the potential to form either endothelial or hematopoietic cells. It exists during embryogenesis in the blood island region of the yolk sac [20], which is therefore the earliest site of hematopoiesis and vasculogenesis. Until recently, vasculogenesis has been thought to be restricted to the yolk sac and the early embryogenesis. However, novel observations have revealed in adulthood a situation consistent with vasculogenesis: endothelial cells derived from angioblasts or "hemangioblasts" previously isolated from peripheral blood or bone marrow are incorporated into sites of neovascularization in physiological and pathological conditions [21-25]. In addition, the number of these endothelial cell progenitors increases in the peripheral blood during tissue ischemia or following the administration of VEGF or GM-CSF, a cytokine known to induce mobilization of hematopoietic stem cells from the bone marrow into the peripheral blood [24,25]. Recent studies in humans, dogs, rats, rabbits and mice have indeed indicated the presence of endothelial precursor cells (EPCs) in bone marrow and peripheral blood during adult life which can be mobilized and incorporated into newly formed vessels or are involved in endothelialization of implants [23,26-32]. Interestingly, in all these experiments, endothelial cell progenitors are isolated together with other hematopoietic stem cells by using antibodies directed against hematopoietic stem cell antigens. PROM-1 is expressed on lineage non-committed stem and progenitor cells but not on mature peripheral blood cells and umbilical vein derived endothelial cells [2]. $CD34^+$ cells co-

expressing VEGFR-2 and PROM-1, have been isolated from peripheral blood, cord blood, fetal liver and bone marrow. When grown in the presence of VEGF and FGF-2 or the cytokine stem cell growth factor (SCGF), these cells give rise to endothelial cells, thus suggesting that this subset of $CD34^+$, $VEGFR\text{-}2^+$ & $CD133^+$ cells may play a role in neovasculogenesis [3,5,11]. The present invention uses a transgenic mouse deficient in PROM-1 to study the involvement of PROM-1 in several pathological models of angiogenesis. For the sake of clarity the nucleotide sequence of human prominin-1 is designated here as SEQ ID NO: 1 and the amino acid sequence of human prominin-1 is designated as SEQ ID NO: 2. The present invention shows that inhibitors of prominin-1 can be used in therapeutic applications for the prevention of pathological angiogenesis.

Thus the invention provides in one embodiment the use of a molecule which comprises a region specifically binding to prominin-1 (SEQ ID NO: 2) or nucleic acids encoding prominin-1 (SEQ ID NO: 1), for the manufacture of a medicament to treat pathological angiogenesis.

According to the invention molecules that comprise a region specifically binding to prominin-1 or nucleic acids encoding prominin-1 which can be used for the manufacture of a medicament to treat pathological angiogenesis can be chosen from the list comprising an antibody or any fragment thereof binding to prominin-1, a (synthetic) peptide, a protein, a small molecule specifically binding to prominin-1 or nucleic acids encoding prominin-1 or a regulatory region (e.g. a promoter region) of prominin-1, RNA aptamers against prominin-1, a ribozyme against nucleic acids encoding prominin-1, anti-sense nucleic acids hybridising with nucleic acids encoding prominin-1 and small interference RNA's (siRNA) against prominin-1.

The wording 'a molecule which comprises a region specifically binding to prominin-1 or nucleic acids encoding prominin-1' relates (1) on the one hand to molecules binding to nucleic acids encoding prominin-1 or to regulatory genetic regions of prominin-1, said molecules inhibit the gene expression of prominin-1 (thus the inhibition of prominin-1 transcription and/or translation of a gene transcript (mRNA) of prominin-1 and (2) on the other hand to molecules that inhibit the activity of the prominin-1 protein. The inhibition of gene expression can be measured conveniently by methods known in the art such as for example RT-PCR analysis of the prominin-1 transcript or for example western blot analysis of the prominin-1 protein, said inhibition is preferably at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or even higher. Measurement of molecules that bind to the

prominin-1 protein and inhibit the activity of prominin-1 can for example be carried out by various methods for determining pathological angiogenesis as described in the examples of the present invention. Said inhibition of prominin-1 activity is preferably at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or even higher. Thus in another embodiment the invention provides the use of a molecule that inhibits the expression and/or activity of prominin-1 for the manufacture of a medicament for treatment of pathological angiogenesis. In the latter embodiment activity relates to the gene product (the protein) and expression relates to the gene: mRNA formation and/or translation of the mRNA of prominin-1.

The term 'antibody' or 'antibodies' relates to an antibody characterized as being specifically directed against prominin-1 or any functional derivative thereof, with said antibodies being preferably monoclonal antibodies; or an antigen-binding fragment thereof, of the $F(ab')_2$, F(ab) or single chain Fv type, or any type of recombinant antibody derived thereof. These antibodies of the invention, including specific polyclonal antisera prepared against prominin-1 or any functional derivative thereof, have no cross-reactivity to others proteins. The monoclonal antibodies of the invention can for instance be produced by any hybridoma liable to be formed according to classical methods from splenic cells of an animal, particularly of a mouse or rat immunized against prominin-1 or any functional derivative thereof, and of cells of a myeloma cell line, and to be selected by the ability of the hybridoma to produce the monoclonal antibodies recognizing prominin-1 or any functional derivative thereof which have been initially used for the immunization of the animals. The monoclonal antibodies according to this embodiment of the invention may be humanized versions of the mouse monoclonal antibodies made by means of recombinant DNA technology, departing from the mouse and/or human genomic DNA sequences coding for H and L chains or from cDNA clones coding for H and L chains. Alternatively the monoclonal antibodies according to this embodiment of the invention may be human monoclonal antibodies. Such human monoclonal antibodies are prepared, for instance, by means of human peripheral blood lymphocytes (PBL) repopulation of severe combined immune deficiency (SCID) mice as described in PCT/EP 99/03605 or by using transgenic non-human animals capable of producing human antibodies as described in US patent 5,545,806. Also fragments derived from these monoclonal antibodies such as Fab, $F(ab)'_2$ and ssFv ("single chain variable fragment"), providing they have retained the original binding properties, form part of the present invention. Such fragments are commonly generated by, for instance, enzymatic digestion of the antibodies with papain, pepsin, or other proteases. It is well known to

the person skilled in the art that monoclonal antibodies, or fragments thereof, can be modified for various uses. The antibodies involved in the invention can be labeled by an appropriate label of the enzymatic, fluorescent, or radioactive type.

In a specific embodiment the antibodies against prominin-1 can be derived from animals of the camelid family. In said family immunoglobulins devoid of light polypeptide chains are found. Heavy chain variable domain sequences derived from camelids are designated as VHH's. "Camelids" comprise old world camelids (*Camelus bactrianus* and *Camelus dromaderius*) and new world camelids (for example *Lama paccos*, *Lama glama* and *Lama vicugna*). EP0656946 describes the isolation and uses of camelid immunoglobulins and is incorporated herein by reference.

Small molecules, e.g. small organic molecules, and other drug candidates can be obtained, for example, from combinatorial and natural product libraries.

Also within the scope of the invention are oligoribonucleotide sequences, that include anti-sense RNA and DNA molecules and ribozymes that function to inhibit the translation of prominin-1 mRNA. Anti-sense RNA and DNA molecules act to directly block the translation of mRNA by binding to targeted mRNA and preventing protein translation. In regard to antisense DNA, oligodeoxyribonucleotides derived from the translation initiation site, e.g., between -10 and +10 regions of the prominin-1 nucleotide sequence, are preferred. Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by an endonucleolytic cleavage. Within the scope of the invention are engineered hammerhead motif ribozyme molecules that specifically and efficiently catalyze endonucleolytic cleavage of prominin-1 RNA sequences.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences, GUA, GUU and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for predicted structural features such as secondary structure that may render the oligonucleotide sequence unsuitable. The suitability of candidate targets may also be evaluated by testing their accessibility to hybridization with complementary oligonucleotides, using ribonuclease protection assays.

Both anti-sense RNA and DNA molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of RNA molecules. These include techniques for chemically synthesizing oligodeoxyribonucleotides well known in

the art such as for example solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors which incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize anti-sense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

In a particular embodiment short interference RNA molecules (siRNA) can be used for the manufacture of a medicament for treatment of pathological angiogenesis. Said interference RNA molecules can be generated based on the genetic sequence of prominin-1 (SEQ ID NO: 1). RNA interference (RNAi) is based on the degradation of particular target sequences by the design of short interference RNA oligo`s (siRNA) which recognize the target sequence (here SEQ ID NO: 1) and subsequently trigger their degradation by a poorly understood pathway. In general siRNA duplexes are shorter than 30 nucleotides, because longer stretches of dsRNA activate the PKR pathway in mammalian cells which results in a global a-specific shut-down of protein synthesis. The preparation and gene therapy vectors for the intracellular expression of siRNAs duplexes is disclosed in WO0244321 which is herein incorporated by reference.

In another particular embodiment RNA aptamers can be used for the manufacture of a medicament for treatment of pathological angiogenesis. Said RNA aptamers can be generated against prominin-1 (SEQ ID NO: 2). Recently, RNA aptamers have been used as therapeutic reagents for their ability to disrupt protein function. Selection of aptamers in vitro allows rapid isolation of extremely rare RNAs that have high specificity and affinity for specific proteins. Exemplary RNA aptamers are described in U.S. Pat. No. 5,270,163 to Gold et al., Ellington and Szostak, "In vitro Selection of RNA Molecules That Bind Specific Ligands," Nature 346:818-822 (1990), and Tuerk and Gold, "Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polymerase," Science 249:505-510 (1990). Unlike antisense compounds, whose targets are one dimensional lattices, RNA aptamers can bind to the three dimensional surfaces of a protein. Moreover, RNA aptamers can frequently discriminate finely among discrete functional sites of a protein (Gold et al., "Diversity of Oligonucleotide Functions," Annu. Rev. Biochem. 64:763-797 (1995)). As research and therapeutic reagents, aptamers not only have the combined advantages of antibodies and small molecular mass drugs, but in vivo production of RNA aptamers also can be

controlled genetically Such RNA expressing genes are usually smaller than protein-coding genes and can be inserted into gene therapy vectors.

The term 'pathological angiogenesis' refers to the excessive formation and growth of blood vessels during the maintenance and the progression of several disease states. Examples where pathological angiogenesis can occur are blood vessels (atherosclerosis, hemangioma, hemangioendothelioma), bone and joints (rheumatoid arthritis, synovitis, bone and cartilage destruction, osteomyelitis, pannus growth, osteophyte formation, neoplasms and metastasis), skin (warts, pyogenic granulomas, hair growth, Kaposi's sarcoma, scar keloids, allergic oedema, neoplasms), liver, kidney, lung, ear and other epithelia (inflammatory and infectious processes (including hepatitis, glomerulonephritis, pneumonia), asthma, nasal polyps, otitis, transplantation, liver regeneration, neoplasms and metastasis), uterus, ovary and placenta (dysfunctional uterine bleeding (due to intrauterine contraceptive devices), follicular cyst formation, ovarian hyperstimulation syndrome, endometriosis, neoplasms), brain, nerves and eye (retinopathy of prematurity, diabetic retinopathy, choroidal and other intraocular disorders, leukomalacia, neoplasms and metastasis), heart and skeletal muscle due to work overload, adipose tissue (obesity), endocrine organs (thyroiditis, thyroid enlargement, pancreas transplantation), hematopoiesis (AIDS (Kaposi), hematologic malignancies (leukemias, etc.), tumour induced new blood vessels.

The term 'medicament to treat' relates to a composition comprising molecules as described above and a pharmaceutically acceptable carrier or excipient (both terms can be used interchangeably) to treat diseases as indicated above. Suitable carriers or excipients known to the skilled man are saline, Ringer's solution, dextrose solution, Hank's solution, fixed oils, ethyl oleate, 5% dextrose in saline, substances that enhance isotonicity and chemical stability, buffers and preservatives. Other suitable carriers include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids and amino acid copolymers. The 'medicament' may be administered by any suitable method within the knowledge of the skilled man. The preferred route of administration is parenterally. In parental administration, the medicament of this invention will be formulated in a unit dosage injectable form such as a solution, suspension or emulsion, in association with the pharmaceutically acceptable excipients as defined above. However, the dosage and mode of administration will depend on the individual. Generally, the medicament is administered so that the protein, peptide, antibody, small molecule, ribozyme, RNA

aptamer, anti-sense nucleic acid or siRNA of the present invention is given at a dose between 1 μg/kg and 10 mg/kg, more preferably between 10 μg/kg and 5 mg/kg, most preferably between 0.1 and 2 mg/kg. Preferably, it is given as a bolus dose. Continuous infusion may also be used and includes continuous subcutaneous delivery via an osmotic minipump. If so, the medicament may be infused at a dose between 5 and 20 μg/kg/minute, more preferably between 7 and 15 μg/kg/minute.

In another embodiment antibodies or functional fragments thereof can be used for the manufacture of a medicament for the treatment of the above mentioned disorders. As a non-limiting example there are the antibodies described in US 5,843,633. In a specific embodiment said antibodies are humanized (Rader et al., 2000, J. Biol. Chem. 275, 13668) and more specifically human antibodies are used to manufacture a medicament to treat pathological angiogenesis. In yet another specific embodiment antibodies derived from camelids are used to manufacture a medicament to treat pathological angiogenesis.

Another aspect of administration for treatment is the use of gene therapy to deliver the above mentioned anti-sense gene or functional parts of the prominin-1 gene or a ribozyme directed against the prominin-1 mRNA or a functional part thereof or RNA aptamers or siRNAs. Gene therapy means the treatment by the delivery of therapeutic nucleic acids to patient's cells. This is extensively reviewed in Lever and Goodfellow 1995; Br. Med Bull.,51, 1-242; Culver 1995; Ledley, F.D. 1995. Hum. Gene Ther. 6, 1129. To achieve gene therapy there must be a method of delivering genes to the patient's cells and additional methods to ensure the effective production of any therapeutic genes. There are two general approaches to achieve gene delivery; these are non-viral delivery and virus-mediated gene delivery.

The invention also provides methods for identifying compounds or molecules which bind on prominin-1 and prevent or suppress pathological angiogenesis. With "suppression" it is understood that said suppression can occur for at least 20%, 30%, 30%, 50%, 60%, 70%, 80%, 90% or even 100%.

Thus in another embodiment the invention provides a method to identify molecules that comprise a region that specifically binds to prominin-1 comprising: (1) exposing prominin-1 or nucleic acids encoding prominin-1 to at least one molecule whose ability to suppress or prevent pathological angiogenesis is sought to be determined, (2) determining binding or hybridising of said molecule(s) to prominin-1 or nucleic acids

encoding prominin-1, and (3) monitoring said pathological angiogenesis when administering said molecules as a medicament.

The latter method is also referred to as 'drug screening assay' or 'bioassay' and typically include the step of screening a candidate/test compound or agent for the ability to interact with prominin-1. Candidate compounds or agents, which have this ability, can be used as drugs to combat or prevent pathological conditions of angiogenesis. Candidate/test compounds are described herein before and are for example RNA aptamers, others are small molecules, e.g. small organic molecules, and other drug candidates can be obtained, for example, from combinatorial and natural product libraries as described above. Typically, the assays are cell-free assays which include the steps of combining prominin-1 and a candidate/test compound (molecule), e.g., under conditions which allow for interaction of (e.g. binding of) the candidate/test compound with prominin-1 to form a complex, and detecting the formation of a complex, in which the ability of the candidate compound to interact with prominin-1 is indicated by the presence of the candidate compound in the complex. Formation of complexes between prominin-1 and the candidate compound can be quantitated, for example, using standard immunoassays. The prominin-1 employed in such a test may be free in solution, affixed to a solid support, borne on a cell surface, or located extracellularly or even intracellularly.

To perform the above described drug screening assays, it is feasible to immobilize prominin-1 or its (their) target molecule(s) to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Interaction (e.g., binding of) of prominin-1 to a target molecule, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtitre plates, test tubes, and microcentrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, prominin-1-His tagged can be adsorbed onto Ni-NTA microtitre plates, or prominin-1-ProtA fusions adsorbed to IgG, which are then combined with the cell lysates (e.g., ^{35}S-labeled) and the candidate compound, and the mixture incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the plates are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly, or in the supernatant after the complexes are dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of prominin-1-binding protein found in the bead fraction quantitated

from the gel using standard electrophoretic techniques. Other techniques for immobilizing protein on matrices can also be used in the drug screening assays of the invention. For example, prominin-1 can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated prominin-1 can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Another technique for drug screening which provides for high throughput screening of compounds having suitable binding affinity to prominin-1 is described in detail in "Determination of Amino Acid Sequence Antigenicity" by Geysen HN, WO 84/03564, published on 13/09/84. In summary, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The protein test compounds are reacted with fragments of prominin-1 and washed. Bound prominin-1 is then detected by methods well known in the art. Purified prominin-1 can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support. This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding prominin-1 specifically compete with a test compound for binding prominin-1. In this manner, the antibodies can be used to detect the presence of any protein, which shares one or more antigenic determinants with prominin-1.

Examples

1. Generation of a prominin-1 knock-out mice

To study the *in vivo* role of PROM-1, PROM-1 (prominin-1) deficient mice were generated. Targeted inactivation of the PROM-1 gene was achieved by deletion of exon 2 (containing the start codon). Briefly, a genomic BAC (bacterial artificial chromosome) containing the murine PROM-1 [1] was obtained from Research Genetics Inc (Huntsville, AL) after screening by PCR and hybridization. Mapping of the murine PROM-1 homologue gene revealed that the first exon, which is 79 bp long, is separated from the second exon by an approximately 8 kb intron. It is the second exon (376 bp long) that contains the startcodon ATG. A BamHI fragment of 11.5 kb containing exon 2 was subcloned into the pUC18 plasmid. A targeting vector for inactivation of the PROM-1 gene, p*PNT*.PROM-1^{null}, was constructed consisting of, from 5' to 3': 1.2 kb of 5' homology comprising the end of intron 1; a *lox*P-flanked *neomycin* gene; 5.5 kb from

intron 2 as 3'-homology; and a *thymidine kinase* selection cassette outside of the regions of homology for counterselection against random integration events. The integrity of the construct was verified by restriction digestion and sequencing. The linearized targeting vector p*PNT*.PROM-1^{null} was electroporated in R1 ES cells and targeted clones were identifed by appropriate Southern blot analysis and used for morula aggregation to generate PROM-1 deficient chimeric and germline mice. PROM-1 deficient mice were born at the expected Mendelian frequency (~25% of 450 offspring from PROM-1 heterozygous breeding pairs). They appeared healthy and were fertile, irrespective of their genetic background (backgrounds tested: 50% Swiss/50% 129, 100% 129, 50% C57Bl6/50% 129). We anticipated that PROM-1 might play a crucial role in hematopoiesis implying that the PROM-1$^{-/-}$ embryo would die *in utero* either after the appearance of the primitive hematopoiesis (7.5 days post coitum, site: yolk sac) or at the emergence of the definitive hematopoiesis (12.5 days post coitum, site: fetal liver). Surprisingly, however, embryonic development in PROM-1$^{-/-}$ mice was normal. PROM-1$^{-/-}$ embryos were not rescued by maternal PROM-1, as PROM-1$^{-/-}$ embryos, sired by PROM-1$^{+/-}$ as well as by PROM-1$^{-/-}$ breeding pairs, developed normally. Also postnatal physiological vascular development seemed normal since no vascular defects could be observed in the heart (capillary density is 5810 ± 154 in PROM-1$^{+/+}$ pups versus 5394 ± 179 in PROM-1$^{-/-}$ pups, n=3; p=NS), kidneys, lungs and skeletal muscle during postnatal growth in PROM-1$^{-/-}$ mice.

2. Impaired pathological angiogenesis and/or vasculogenesis in prominin-1 knock-out mice

In order to study the role of PROM-1 in pathological conditions of angiogenesis PROM-1$^{-/-}$ mice and their wild-type littermates are subjected to various murine models of pathological blood vessel formation.

2.1 Ischemic retinopathy

PROM-1$^{-/-}$ mice and their wild-type littermates were subjected to a mouse model of ischemic retinopathy. In this hyperoxia-induced retinopathy model, neonatal mice (with an immature retinal vasculature) are exposed to hyperoxia, resulting in obliteration of the developing blood vessels supplying oxygen to the retina. When the mice are then returned to normoxia, the retina, distal to the occluded vessels, becomes ischemic,

inducing VEGF production and ultimately resulting in reproducible and quantifiable proliferative retinal neovascularization (33, 34). This model, which mimicks to a certain extent the vascular response during retinopathy of prematurity or diabetic retinopathy, may be useful to test the efficacy of (anti)-angiogenic molecules (Pierce EA et al (1995) Proc. Natl. Acad. Sci. 92(3)905-9). Mouse pups of 7 days (P7) together with their mothers, are subjected to hyperoxia (75% oxygen) in specially designed oxygen chambers for 5 days, without opening the cages. On P12, the animals are returned to room air until P17, when the retinas are assessed for maximal neovascular response. Anaesthetized mice are perfused through the left ventricle with 1 ml of phosphate buffered saline containing 50 mg of $2x10^6$ molecular weight fluorescein-dextran. The eyes are removed and fixed in 4% paraformaldehyde for 3 (right eye) or 24 (left eye) hrs. Of the right eyes, lenses are removed and peripheral retinas cut to allow flat mounting with glycerol-gelatin. The flat mounted retinas are analyzed by fluorescence microscopy. The left eyes are embedded in paraffin and serial 6 μm sections are cut sagittally throughout the cornea, parallel to the optic nerve, and stained with hematoxylin-eosin. The proliferative neovascular response is quantified by counting the number of new vessels (= tufts) and the number of endothelial cells extending from the internal limiting membrane of the retina into the vitreum on the stained sagittal cross-sections. The angiographic technique using fluorescein-dextran perfusion is used in conjunction with this counting method for rapid screening of retinas or as an alternative grading system for quantitative evaluation. Loss of prominin-1 significantly protected mice against intra-vitreous neovascularization, as evaluated by counting the number of neovascular tufts and endothelial cells (EC) in the vitrous cavity (n=15; $p<0.001$)

	N° of tufts in vitreous cavity (per 10 retinal sections)	N° of EC in vitreous cavity (per 10 retinal sections)
PROM-1$^{-/-}$ $^{+/+}$ pups (n = 15)	157.1 ± 13.6	286.0 ± 45.1
PROM-1$^{-/-}$ pups (n = 15)	72.5 ± 14.6	106.2 ± 22.6

2.2 Corneal micropocket assay

Hydron pellets containing an angiogenic substance (like bFGF or VEGF) are implanted into the corneal stroma adjacent to the temporal limbus. This induces neovascularization of the avascular corneal stroma from day 3 to day 8 after implantation, without substantial corneal edema or inflammation. Like the retinal hypoxia model, it gives a predictable, persistent and aggressive neovascular response, which is dependent on direct stimulation of blood vessels rather than on indirect stimulation by the induction of inflammation [35]. The mouse corneal micropocket assay was performed as previously described [36]. Hydron-coated sucralfate pellets containing 300 ng of $VEGF_{165}$ were positioned 1 mm from the corneal limbus. Mice deficient for PROM-1 showed a reduced angiogenic response. The length of the newly formed vessels (0.93 ± 0.12 mm in PROM-$1^{+/+}$ mice versus 0.70 ± 0.03 mm in PROM-$1^{-/-}$ mice, n=6; $p<0.005$) as well as the circumferential neovascularity (6.23 ± 0.55 mm in PROM-$1^{+/+}$ mice versus 3.60 ± 0.32 mm in PROM-$1^{-/-}$ mice, n=6; $p<0.005$) and the integrated optical density of the vessel area (497 ± 100 in PROM-$1^{+/+}$ mice versus 196 ± 27 in PROM-$1^{-/-}$ mice, n=6; $p<0.05$) were significantly lower in the PROM-1 mice. Moreover, WT bone marrow transplantation into PROM-1 deficient mice rescued the impaired angiogenic response. The length of the newly formed vessels (0.57 ± 0.03 mm in PROM-$1^{+/+}$ mice versus 0.57 ± 0.03 mm in PROM-$1^{-/-}$ mice, n=6; $p<0.005$) as well as the circumferential neovascularity (3.52 ± 0.26 mm in PROM-$1^{+/+}$ mice versus 3.29 ± 0.22 mm in PROM-$1^{-/-}$ mice, n=6; p=NS) were identical in both PROM-1 deficient and WT mice after WT bone marrow transplantation.

2.3 Model of skin wound healing

Vascular remodeling was studied in a model of skin wound healing as described before [37,38]. For skin wounding, a standardised 15 mm full-thickness skin incision was made on the back of the mice, taking care not to damage the underlying muscle. Wound healing was quantified by daily measuring the width and the length of the wound. New blood vessel formation was analysed on skin sections harvested four days after wounding. Wound healing was significantly impaired in the PROM-1 deficient mice. Both genotypes contained comparable densities of vessels in unwounded skin. However, the number of capillaries infiltrating the wound (185.8 ± 11.1 vessels/mm^2 in PROM-$1^{+/+}$ mice versus 135.0± 12.7 in PROM-$1^{-/-}$ mice, n=5; $p<0.05$), as well as the number of

smooth muscle-coated vessels in the wounded area (58.2 ± 10 vessels/mm^2 in PROM-1$^{+/+}$ mice versus 28.6 ± 4.022 in PROM-1$^{-/-}$ mice, n=5; p<0.05) were significantly reduced in PROM-1 deficient mice.

2.4 Matrigel assay

In-growth of capillaries was studied in a matrigel assay performed as described [39]. The angiogenic response in the matrigel of PROM-1$^{-/-}$ mice seemed somewhat lower as measured by the hemoglobin content per matrigel implant (137.0 ± 20.4 µg/ml in PROM-1$^{+/+}$ mice *versus* 112.1 ± 17.6 µg/ml in PROM-1$^{-/-}$ mice; n=15; p= NS). Histological sections of matrigel were then analysed for infiltration of leukocytes and for blood vessel formation after staining for inflammatory cells (CD45) and endothelial cells (CD31), respectively. The number of infiltrating leukocytes did not seem to differ but a reduced blood vessel formation (CD31 positive endothelial cells) was noticed in the matrigel implanted in PROM-1 deficient animals (% of CD31 positive area in matrigel: 0.55 ± 0.08% in PROM-1$^{+/+}$ mice *versus* 0.26 ± 0.06% in PROM-1$^{-/-}$ mice; n=5; p<0.05).

2.5 Myocardial infarction model

Myocardial infarction was performed by ligation of the LAD as described [40]. After 4 to 7 days, infarcted hearts were used for histological analysis or for immunostaining of thrombomodulin (endothelial cells) or smooth muscle alpha-actin (smooth muscle cells) [38]. Morphometric analysis and counting of immunoreactive cells was performed using an image analysis system with KS300 software (Zeiss, Brussels, Belgium). No differences were observed in the number of capillaries at 4 (490.9 ± 65.4 vessels/mm^2 in PROM-1$^{+/+}$ mice *versus* 493.3 ± 87.7 vessels/mm^2 in PROM-1$^{-/-}$ mice; n=3; p= NS) or 7 days (510.6 ± 28.3 vessels/mm^2 in PROM-1$^{+/+}$ mice *versus* 507.8 ± 24.6 vessels/mm^2 in PROM-1$^{-/-}$ mice; n=10; p= NS) after ligation or in the number of SMC covered vessels at 4 (20.3 ± 3.2 vessels/mm^2 in PROM-1$^{+/+}$ mice *versus* 23.3 ± 6.73 vessels/mm^2 in PROM-1$^{-/-}$ mice; n=3; p= NS) or at 7 days (87.6 ± 14.3 vessels/mm^2 in PROM-1$^{+/+}$ mice *versus* 76.4 ± 12.2 vessels/mm^2 in PROM-1$^{-/-}$ mice; n=10; p= NS) in the infarcted area of hearts of PROM-1 deficient mice and wild-type littermates. However, a clear significant difference was observed in the number of infiltrating macrophages at 7 days after ligation (% of Mac3 positive area: 3.75 ± 0.77 % in PROM-1$^{+/+}$ mice *versus* 1.62 ± 0.42 % in PROM-1$^{-/-}$ mice; n=10; p< 0.05).

2.6 Hind limb ischemia model

Hind limb ischemia is induced as described [41]. Unilateral right or bilateral ligations of the femoral artery and vein (proximal to the popliteal artery) and the cutaneous vessels branching from the caudal femoral artery side branch is be performed and two superficial preexisting collateral arterioles, connecting the femoral and saphenous artery, will be used for analysis. Genetic consequences on post-ischemic revascularization is determined 14 days after ligation, using vascular morphological (histological evaluation of capillary density and SMC-coated vessel density, histological evaluation of myocyte necrosis and regeneration), perfusional (fluorescent microspheres, laser Doppler imaging), and functional (graded treadmill exercise or swim endurance exercise) analyses.

2.7 Tumor models

The role of PROM-1 is also tested in tumor models. The following mouse models are operational and are used to analyze tumor angiogenesis in vivo: 1) subcutaneous injection of ras-transformed fibroblasts in athymic nude (nu/nu) mice, 2) subcutaneous injection of Lewis lung carcinoma cells in syngenic C57Bl6 hosts, and 3) subcutaneous inoculation of rat C6 glioma cells of athymic nude (nu/nu) mice. Five to twenty million of tumor cells are inoculated in the mice and tumor growth is followed up to 30 days. Tumors are measured with calipers and tumor volumes calculated using the formula [π/6 x (w1 x w2 x w2)], where "w1" and "w2" represent the largest and smallest tumor diameter, respectively. Tumor vessel density and size are determined on tissue sections using immunohistochemistry for visualization of endothelial cells (CD-31), in combination with quantitative morphometry of vascular densities and patterning. If necessary, intratumor flow is determined using colored microspheres to quantitate flow across the entire tumor. When WT RAS transformed fibroblasts were injected in PROM-1 deficient and WT nude mice, no difference in tumor weight was seen (tumor weight after 14 days: 0.9 ± 0.1 g in PROM-$1^{+/+}$ hosts versus 1.1 ± 0.3 g in PROM-$1^{-/-}$ hosts; n=7; $p < 0.05$). Blood vessel analysis is being performed. Remarkably, the number of infiltrating leukocytes was significantly reduced in the tumors grown in the PROM-1 deficient mice.

2.8 LPS induced venous thrombosis in footpad

To study whether PROM-1 is important in inflammatory processes, a chronic

inflammation footpad assay was used. Endotoxin (20µl, E. coli lipopolysaccharide, 5 and 50 µg/ml) was injected into the right footpad of both PROM-1 deficient and WT mice as described (Carmeliet, P. et al (1993) J. Clin. Invest 6: 2756-60). Saline is injected into the left footpad as a control. After 5 days, mice were sacrificed and both right and left footpad were measured with callipers, excised and fixed in 1% paraformaldehyde for 24 hours. Subsequently, footpads were embedded in paraffin and sectioned. Veins are scored on haematoxilin and eosin stained sections for the presence of thrombi. Five days after injecting 50 µg/ml of endotoxin, a decrease in footpad thickness was observed in the PROM-1 deficient compared to their WT controls.

These data clearly indicate a role of AC 133 in pathological vasculogenesis and/or angiogenesis and implicate the use of inhibitors of PROM-1 in therapeutic strategies to inhibit blood vessel formation in various pathological disorders.

References

1. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997;90(12):5013-21.
2. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW. PROM-1, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90(12):5002-12.
3. Gehling UM, Ergun S, Schumacher U, Wagener C, Pantel K, Otte M, Schuch G, Schafhausen P, Mende T, Kilic N and others. In vitro differentiation of endothelial cells from PROM-1-positive progenitor cells. Blood 2000;95(10):3106-12.
4. Boyer M, Townsend LE, Vogel LM, Falk J, Reitz-Vick D, Trevor KT, Villalba M, Bendick PJ, Glover JL. Isolation of endothelial cells and their progenitor cells from human peripheral blood. J Vasc Surg 2000;31(1 Pt 1):181-9.
5. Quirici N, Soligo D, Caneva L, Servida F, Bossolasco P, Deliliers GL. Differentiation and expansion of endothelial cells from human bone marrow CD133(+) cells. Br J Haematol 2001;115(1):186-94.
6. Buhring HJ, Seiffert M, Bock TA, Scheding S, Thiel A, Scheffold A, Kanz L, Brugger W. Expression of novel surface antigens on early hematopoietic cells. Ann N Y Acad Sci 1999;872:25-38; discussion 38-9.
7. Horn PA, Tesch H, Staib P, Kube D, Diehl V, Voliotis D. Expression of PROM-1, a novel hematopoietic precursor antigen, on acute myeloid leukemia cells. Blood 1999;93(4):1435-7.
8. Kratz-Albers K, Zuhlsdorp M, Leo R, Berdel WL, Buchner T, Serve H. Expression of a PROM-1, a novel stem cell marker, on human leukemic blasts lacking CD34-antigen and on a human CD34+ leukemic line:MUTZ-2. Blood 1998;92(11):4485-7.
9. Buhring HJ, Seiffert M, Marxer A, Weiss B, Faul C, Kanz L, Brugger W. PROM-1 antigen expression is not restricted to acute myeloid leukemia blasts but is also found on acute lymphoid leukemia blasts and on a subset of CD34+ B-cell precursors. Blood 1999;94(2):832-3.
10. Corbeil D, Roper K, Hannah MJ, Hellwig A, Huttner WB. Selective localization of the polytopic membrane protein prominin in microvilli of epithelial cells - a combination of apical sorting and retention in plasma membrane protrusions. J Cell Sci 1999;112(Pt 7):1023-33.

11. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA and others. Expression of VEGFR-2 and PROM-1 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000;95(3):952-8.

12. Rafii S. Circulating endothelial precursors: mystery, reality, and promise. J Clin Invest 2000;105(1):17-9.

13. Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, Weissman IL. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A 2000;97(26):14720-5.

14. Corbeil D, Roper K, Hellwig A, Tavian M, Miraglia S, Watt SM, Simmons PJ, Peault B, Buck DW, Huttner WB. The human PROM-1 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 2000;275(8):5512-20.

15. Yu Y, Flint A, Dvorin EL, Bischoff J. PROM-1-2, a Novel Isoform of Human PROM-1 Stem Cell Antigen. J Biol Chem 2002;277(23):20711-6.

16. Maw MA, Corbeil D, Koch J, Hellwig A, Wilson-Wheeler JC, Bridges RJ, Kumaramanickavel G, John S, Nancarrow D, Roper K and others. A frameshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. Hum Mol Genet 2000;9(1):27-34.

17. Corbeil D, Roper K, Fargeas CA, Joester A, Huttner WB. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2001;2(2):82-91.

18. Corbeil D, Roper K, Weigmann A, Huttner WB. PROM-1 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family? Blood 1998;91(7):2625-6.

19. Miraglia S, Godfrey W, Buck D. A response to PROM-1 hematopoietic stem cell antigen: human homologue of mouse kidney prominin or distinct member of a novel protein family? Blood 1998;91(11):4390-1.

20. Risau W. Mechanisms of angiogenesis. Nature 1997;386(6626):671-4.

21. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275(5302):964-7.

22. Shi Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, Fujita Y, Kothari S, Mohle R, Sauvage LR and others. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998;92(2):362-7.

23. Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Asahara T. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 1999;5(4):434-8.

24. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999;85(3):221-8.

25. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai Y, Silver M, Isner JM. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. Embo J 1999;18(14):3964-72.

26. Bhattacharya V, McSweeney PA, Shi Q, Bruno B, Ishida A, Nash R, Storb RF, Sauvage LR, Hammond WP, Wu MH. Enhanced endothelialization and microvessel formation in polyester grafts seeded with CD34(+) bone marrow cells. Blood 2000;95(2):581-5.

27. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, Kearney M, Li T, Isner JM, Asahara T. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci U S A 2000;97(7):3422-7.

28. Schatteman GC, Hanlon HD, Jiao C, Dodds SG, Christy BA. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J Clin Invest 2000;106(4):571-8.

29. Kawamoto A, Gwon HC, Iwaguro H, Yamaguchi JI, Uchida S, Masuda H, Silver M, Ma H, Kearney M, Isner JM and others. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001;103(5):634-7.

30. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, Homma S, Edwards NM, Itescu S. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001;7(4):430-6.

31. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001;89(1):E1-7.

32. Gill M, Dias S, Hattori K, Rivera ML, Hicklin D, Witte L, Girardi L, Yurt R, Himel H, Rafii S. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)PROM-1(+) endothelial precursor cells. Circ Res 2001;88(2):167-74.

33. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R, D'Amore PA. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994;35(1):101-11.

34. Wesolowski E, Smith LE. Effect of light on oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994;35(1):112-9.

35. Kenyon BM, Voest EE, Chen CC, Flynn E, Folkman J, D'Amato RJ. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 1996;37(8):1625-32.

36. Asahara T, Chen D, Takahashi T, Fujikawa K, Kearney M, Magner M, Yancopoulos GD, Isner JM. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF- induced postnatal neovascularization. Circ Res 1998;83(3):233-40.

37. Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG, Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 1995;270(21):12607-13.

38. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H and others. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7(5):575-83.

39. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS, Martin GR. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992;67(4):519-28.

40. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, Angellilo A and others. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999;5(10):1135-42.

41. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F, Nagy JA, Hooper A, Priller J, De Klerck B and others. Revascularization of ischemic tissues by

PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8(8):831-40.

42. Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999;13(9):1055-66.

43. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6(4):389-95.

44. Breiteneder-Geleff S, Soleiman A, Kowalski H, Horvat R, Amann G, Kriehuber E, Diem K, Weninger W, Tschachler E, Alitalo K and others. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999;154(2):385-94.

45. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 1999;98(6):769-78.

46. Jackson DG, Prevo R, Clasper S, Banerji S. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol 2001;22(6):317-21.

47. Veikkola T, Jussila L, Makinen T, Karpanen T, Jeltsch M, Petrova TV, Kubo H, Thurston G, McDonald DM, Achen MG and others. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. Embo J 2001;20(6):1223-31.

48. Sleeman JP, Krishnan J, Kirkin V, Baumann P. Markers for the lymphatic endothelium: in search of the holy grail? Microsc Res Tech 2001;55(2):61-9.

49. Witte MH, Bernas MJ, Martin CP, Witte CL. Lymphangiogenesis and lymphangiodysplasia: from molecular to clinical lymphology. Microsc Res Tech 2001;55(2):122-45.

50. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, Alitalo K. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001;61(5):1786-90.

51. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson DG and others. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. Embo J 2001;20(4):672-82.

52. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001;7(2):192-8.

53. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001;7(2):186-91.

54. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002;1(3):219-27.

55. Oliver G, Detmar M. The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev 2002;16(7):773-83.

56. Schneider M, Othman-Hassan K, Christ B, Wilting J. Lymphangioblasts in the avian wing bud. Dev Dyn 1999;216(4-5):311-9.

57. Kubo H, Cao R, Brakenhielm E, Makinen T, Cao Y, Alitalo K. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci U S A 2002;99(13):8868-73.

58. Folkman J. A mechanism for regulation of lymphangiogenesis independent of angiogenesis. Bethesda; 2002.

59. Baldwin M, Catimel B, Nice EC, Roufail S, Hall NE, Stenvers KL, Karkkainen MJ, Alitalo K, Stacker SA, M.G. A. The Specificity of Receptor Binding by Vascular Endothelial Growth Factor-D Is Different in Mouse and Man. J. Biol. Chem. 2001;276(22):19166-19171.

60. Boardman KC, Swartz MA. Lymphangiogenesis in a mouse tail model. 2001. p 671-672.

61. Ikomi F, Ohhhashi T. Immunohistochemical expression of VEGF receptors on new vascularization of collecting lymphatics in mice. In: Editore M, editor; 2001; Sidney, Australia. p 387-390.

62. Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992;255(5052):1707-10.

63. Gage FH. Mammalian neural stem cells. Science 2000;287(5457):1433-8.

64. Yamamoto S, Yamamoto N, Kitamura T, Nakamura K, Nakafuku M. Proliferation of parenchymal neural progenitors in response to injury in the adult rat spinal cord. Exp Neurol 2001;172(1):115-27.

65. Cao Q, Benton RL, Whittemore SR. Stem cell repair of central nervous system injury. J Neurosci Res 2002;68(5):501-10.

66. Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med 2002;8(9):963-70.

67. Kempermann G, Kuhn HG, Gage FH. Genetic influence on neurogenesis in the dentate gyrus of adult mice. Proc Natl Acad Sci U S A 1997;94(19):10409-14.

68. Kuhn HG, Palmer TD, Fuchs E. Adult neurogenesis: a compensatory mechanism for neuronal damage. Eur Arch Psychiatry Clin Neurosci 2001;251(4):152-8.

69. Gritti A, Parati EA, Cova L, Frolichsthal P, Galli R, Wanke E, Faravelli L, Morassutti DJ, Roisen F, Nickel DD and others. Multipotential stem cells from the adult mouse brain proliferate and self-renew in response to basic fibroblast growth factor. J Neurosci 1996;16(3):1091-100.

70. Takagi Y, Mitsui A, Nishiyama A, Nozaki K, Sono H, Gon Y, Hashimoto N, Yodoi J. Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. Proc Natl Acad Sci U S A 1999;96(7):4131-6.

71. Tamaki S, Eckert K, He D, Sutton R, Doshe M, Jain G, Tushinski R, Reitsma M, Harris B, Tsukamoto A and others. Engraftment of sorted/expanded human central nervous system stem cells from fetal brain. J Neurosci Res 2002;69(6):976-86.

72. Wu S, Suzuki Y, Kitada M, Kataoka K, Kitaura M, Chou H, Nishimura Y, Ide C. New method for transplantation of neurosphere cells into injured spinal cord through cerebrospinal fluid in rat. Neurosci Lett 2002;318(2):81-4.

73. Lang-Lazdunski L, Matsushita K, Hirt L, Waeber C, Vonsattel JP, Moskowitz MA, Dietrich WD. Spinal cord ischemia. Development of a model in the mouse. Stroke 2000;31(1):208-13.

74. Rapalino O, Lazarov-Spiegler O, Agranov E, Velan GJ, Yoles E, Fraidakis M, Solomon A, Gepstein R, Katz A, Belkin M and others. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med 1998;4(7):814-21.

Claims

1. Use of a molecule that inhibits the expression and/or activity of prominin-1 for the manufacture of a medicament for treatment of pathological angiogenesis.

2. Use of a molecule according to claim 1 wherein said molecule is chosen from the list comprising an antibody or any fragment thereof, a small molecule, an RNA aptamer, a peptide, a ribozyme, anti-sense nucleic acids and siRNA.

3. A method to identify molecules that comprise a region that specifically binds to prominin-1 comprising:
   - exposing prominin-1 or nucleic acids encoding prominin-1 to at least one molecule whose ability to suppress or prevent pathological angiogenesis is sought to be determined,
   - determining binding or hybridising of said molecule(s) to prominin-1 or nucleic acids encoding prominin-1, and
   - monitoring said pathological angiogenesis when administering said molecules as a medicament.

SEQUENCE LISTING

<110> VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW

<120> A NOVEL TARGET TO INHIBIT ANGIOGENESIS

<130> VIB-034-PCT

<150> EP02075544.3
<151> 2002-02-08

<150> EP02077742.1
<151> 2002-07-09

<150> EP03100148.0
<151> 2003-01-24

<160> 2

<170> PatentIn version 3.1

<210> 1
<211> 3794
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (38)..(2635)
<223>

<400> 1
ccaagttcta cctcatgttt ggaggatctt gctagct atg gcc ctc gta ctc ggc 55
Met Ala Leu Val Leu Gly
1 5

tcc ctg ttg ctg ctg ggg ctg tgc ggg aac tcc ttt tca gga ggg cag 103

```
Ser Leu Leu Leu Leu Gly Leu Cys Gly Asn Ser Phe Ser Gly Gly Gln
            10                  15                  20

cct tca tcc aca gat gct cct aag gct tgg aat tat gaa ttg cct gca      151
Pro Ser Ser Thr Asp Ala Pro Lys Ala Trp Asn Tyr Glu Leu Pro Ala
        25                  30                  35

aca aat tat gag acc caa gac tcc cat aaa gct gga ccc att ggc att      199
Thr Asn Tyr Glu Thr Gln Asp Ser His Lys Ala Gly Pro Ile Gly Ile
    40                  45                  50

ctc ttt gaa cta gtg cat atc ttt ctc tat gtg gta cag ccg cgt gat      247
Leu Phe Glu Leu Val His Ile Phe Leu Tyr Val Val Gln Pro Arg Asp
55                  60                  65                  70

ttc cca gaa gat act ttg aga aaa ttc tta cag aag gca tat gaa tcc      295
Phe Pro Glu Asp Thr Leu Arg Lys Phe Leu Gln Lys Ala Tyr Glu Ser
                75                  80                  85

aaa att gat tat gac aag cca gaa act gta atc tta ggt cta aag att      343
Lys Ile Asp Tyr Asp Lys Pro Glu Thr Val Ile Leu Gly Leu Lys Ile
            90                  95                  100

gtc tac tat gaa gca ggg att att cta tgc tgt gtc ctg ggg ctg ctg      391
Val Tyr Tyr Glu Ala Gly Ile Ile Leu Cys Cys Val Leu Gly Leu Leu
        105                 110                 115

ttt att att ctg atg cct ctg gtg ggg tat ttc ttt tgt atg tgt cgt      439
Phe Ile Ile Leu Met Pro Leu Val Gly Tyr Phe Phe Cys Met Cys Arg
    120                 125                 130

tgc tgt aac aaa tgt ggt gga gaa atg cac cag cga cag aag gaa aat      487
Cys Cys Asn Lys Cys Gly Gly Glu Met His Gln Arg Gln Lys Glu Asn
135                 140                 145                 150

ggg ccc ttc ctg agg aaa tgc ttt gca atc tcc ctg ttg gtg att tgt      535
Gly Pro Phe Leu Arg Lys Cys Phe Ala Ile Ser Leu Leu Val Ile Cys
                155                 160                 165

ata ata ata agc att ggc atc ttc tat ggt ttt gtg gca aat cac cag      583
Ile Ile Ile Ser Ile Gly Ile Phe Tyr Gly Phe Val Ala Asn His Gln
            170                 175                 180

gta aga acc cgg atc aaa agg agt cgg aaa ctg gca gat agc aat ttc      631
Val Arg Thr Arg Ile Lys Arg Ser Arg Lys Leu Ala Asp Ser Asn Phe
        185                 190                 195

aag gac ttg cga act ctc ttg aat gaa act cca gag caa atc aaa tat      679
Lys Asp Leu Arg Thr Leu Leu Asn Glu Thr Pro Glu Gln Ile Lys Tyr
    200                 205                 210

ata ttg gcc cag tac aac act acc aag gac aag gcg ttc aca gat ctg      727
Ile Leu Ala Gln Tyr Asn Thr Thr Lys Asp Lys Ala Phe Thr Asp Leu
215                 220                 225                 230

aac agt atc aat tca gtg cta gga ggc gga att ctt gac cga ctg aga      775
Asn Ser Ile Asn Ser Val Leu Gly Gly Gly Ile Leu Asp Arg Leu Arg
                235                 240                 245

ccc aac atc atc cct gtt ctt gat gag att aag tcc atg gca aca gcg      823
Pro Asn Ile Ile Pro Val Leu Asp Glu Ile Lys Ser Met Ala Thr Ala
            250                 255                 260

atc aag gag acc aaa gag gcg ttg gag aac atg aac agc acc ttg aag      871
Ile Lys Glu Thr Lys Glu Ala Leu Glu Asn Met Asn Ser Thr Leu Lys
        265                 270                 275

agc ttg cac caa caa agt aca cag ctt agc agc agt ctg acc agc gtg      919
```

```
Ser Leu His Gln Gln Ser Thr Gln Leu Ser Ser Ser Leu Thr Ser Val
    280                 285                 290

aaa act agc ctg cgg tca tct ctc aat gac cct ctg tgc ttg gtg cat      967
Lys Thr Ser Leu Arg Ser Ser Leu Asn Asp Pro Leu Cys Leu Val His
295                 300                 305                 310

cca tca agt gaa acc tgc aac agc atc aga ttg tct cta agc cag ctg     1015
Pro Ser Ser Glu Thr Cys Asn Ser Ile Arg Leu Ser Leu Ser Gln Leu
                315                 320                 325

aat agc aac cct gaa ctg agg cag ctt cca ccc gtg gat gca gaa ctt     1063
Asn Ser Asn Pro Glu Leu Arg Gln Leu Pro Pro Val Asp Ala Glu Leu
            330                 335                 340

gac aac gtt aat aac gtt ctt agg aca gat ttg gat ggc ctg gtc caa     1111
Asp Asn Val Asn Asn Val Leu Arg Thr Asp Leu Asp Gly Leu Val Gln
        345                 350                 355

cag ggc tat caa tcc ctt aat gat ata cct gac aga gta caa cgc caa     1159
Gln Gly Tyr Gln Ser Leu Asn Asp Ile Pro Asp Arg Val Gln Arg Gln
    360                 365                 370

acc acg act gtc gta gca ggt atc aaa agg gtc ttg aat tcc att ggt     1207
Thr Thr Thr Val Val Ala Gly Ile Lys Arg Val Leu Asn Ser Ile Gly
375                 380                 385                 390

tca gat atc gac aat gta act cag cgt ctt cct att cag gat ata ctc     1255
Ser Asp Ile Asp Asn Val Thr Gln Arg Leu Pro Ile Gln Asp Ile Leu
                395                 400                 405

tca gca ttc tct gtt tat gtt aat aac act gaa agt tac atc cac aga     1303
Ser Ala Phe Ser Val Tyr Val Asn Asn Thr Glu Ser Tyr Ile His Arg
            410                 415                 420

aat tta cct aca ttg gaa gag tat gat tca tac tgg tgg ctg ggt ggc     1351
Asn Leu Pro Thr Leu Glu Glu Tyr Asp Ser Tyr Trp Trp Leu Gly Gly
        425                 430                 435

ctg gtc atc tgc tct ctg ctg acc ctc atc gtg att ttt tac tac ctg     1399
Leu Val Ile Cys Ser Leu Leu Thr Leu Ile Val Ile Phe Tyr Tyr Leu
    440                 445                 450

ggc tta ctg tgt ggc gtg tgc ggc tat gac agg cat gcc acc ccg acc     1447
Gly Leu Leu Cys Gly Val Cys Gly Tyr Asp Arg His Ala Thr Pro Thr
455                 460                 465                 470

acc cga ggc tgt gtc tcc aac acc gga ggc gtc ttc ctc atg gtt gga     1495
Thr Arg Gly Cys Val Ser Asn Thr Gly Gly Val Phe Leu Met Val Gly
                475                 480                 485

gtt gga tta agt ttc ctc ttt tgc tgg ata ttg atg atc att gtg gtt     1543
Val Gly Leu Ser Phe Leu Phe Cys Trp Ile Leu Met Ile Ile Val Val
            490                 495                 500

ctt acc ttt gtc ttt ggt gca aat gtg gaa aaa ctg atc tgt gaa cct     1591
Leu Thr Phe Val Phe Gly Ala Asn Val Glu Lys Leu Ile Cys Glu Pro
        505                 510                 515

tac acg agc aag gaa tta ttc cgg gtt ttg gat aca ccc tac tta cta     1639
Tyr Thr Ser Lys Glu Leu Phe Arg Val Leu Asp Thr Pro Tyr Leu Leu
    520                 525                 530

aat gaa gac tgg gaa tac tat ctc tct ggg aag cta ttt aat aaa tca     1687
Asn Glu Asp Trp Glu Tyr Tyr Leu Ser Gly Lys Leu Phe Asn Lys Ser
535                 540                 545                 550

aaa atg aag ctc act ttt gaa caa gtt tac agt gac tgc aaa aaa aat     1735
```

```
Lys Met Lys Leu Thr Phe Glu Gln Val Tyr Ser Asp Cys Lys Lys Asn
                555                 560                 565

aga ggc act tac ggc act ctt cac ctg cag aac agc ttc aat atc agt     1783
Arg Gly Thr Tyr Gly Thr Leu His Leu Gln Asn Ser Phe Asn Ile Ser
            570                 575                 580

gaa cat ctc aac att aat gag cat act gga agc ata agc agt gaa ttg     1831
Glu His Leu Asn Ile Asn Glu His Thr Gly Ser Ile Ser Ser Glu Leu
        585                 590                 595

gaa agt ctg aag gta aat ctt aat atc ttt ctg ttg ggt gca gca gga     1879
Glu Ser Leu Lys Val Asn Leu Asn Ile Phe Leu Leu Gly Ala Ala Gly
    600                 605                 610

aga aaa aac ctt cag gat ttt gct gct tgt gga ata gac aga atg aat     1927
Arg Lys Asn Leu Gln Asp Phe Ala Ala Cys Gly Ile Asp Arg Met Asn
615                 620                 625                 630

tat gac agc tac ttg gct cag act ggt aaa tcc ccc gca gga gtg aat     1975
Tyr Asp Ser Tyr Leu Ala Gln Thr Gly Lys Ser Pro Ala Gly Val Asn
                635                 640                 645

ctt tta tca ttt gca tat gat cta gaa gca aaa gca aac agt ttg ccc     2023
Leu Leu Ser Phe Ala Tyr Asp Leu Glu Ala Lys Ala Asn Ser Leu Pro
            650                 655                 660

cca gga aat ttg agg aac tcc ctg aaa aga gat gca caa act att aaa     2071
Pro Gly Asn Leu Arg Asn Ser Leu Lys Arg Asp Ala Gln Thr Ile Lys
        665                 670                 675

aca att cac cag caa cga gtc ctt cct ata gaa caa tca ctg agc act     2119
Thr Ile His Gln Gln Arg Val Leu Pro Ile Glu Gln Ser Leu Ser Thr
    680                 685                 690

cta tac caa agc gtc aag ata ctt caa cgc aca ggg aat gga ttg ttg     2167
Leu Tyr Gln Ser Val Lys Ile Leu Gln Arg Thr Gly Asn Gly Leu Leu
695                 700                 705                 710

gag aga gta act agg att cta gct tct ctg gat ttt gct cag aac ttc     2215
Glu Arg Val Thr Arg Ile Leu Ala Ser Leu Asp Phe Ala Gln Asn Phe
                715                 720                 725

atc aca aac aat act tcc tct gtt att att gag gaa act aag aag tat     2263
Ile Thr Asn Asn Thr Ser Ser Val Ile Ile Glu Glu Thr Lys Lys Tyr
            730                 735                 740

ggg aga aca ata ata gga tat ttt gaa cat tat ctg cag tgg atc gag     2311
Gly Arg Thr Ile Ile Gly Tyr Phe Glu His Tyr Leu Gln Trp Ile Glu
        745                 750                 755

ttc tct atc agt gag aaa gtg gca tcg tgc aaa cct gtg gcc acc gct     2359
Phe Ser Ile Ser Glu Lys Val Ala Ser Cys Lys Pro Val Ala Thr Ala
    760                 765                 770

cta gat act gct gtt gat gtc ttt ctg tgt agc tac att atc gac ccc     2407
Leu Asp Thr Ala Val Asp Val Phe Leu Cys Ser Tyr Ile Ile Asp Pro
775                 780                 785                 790

ttg aat ttg ttt tgg ttt ggc ata gga aaa gct act gta ttt tta ctt     2455
Leu Asn Leu Phe Trp Phe Gly Ile Gly Lys Ala Thr Val Phe Leu Leu
                795                 800                 805

ccg gct cta att ttt gcg gta aaa ctg gct aag tac tat cgt cga atg     2503
Pro Ala Leu Ile Phe Ala Val Lys Leu Ala Lys Tyr Tyr Arg Arg Met
            810                 815                 820

gat tcg gag gac gtg tac gat gat gtt gaa act ata ccc atg aaa aat     2551
```

Asp Ser Glu Asp Val Tyr Asp Asp Val Glu Thr Ile Pro Met Lys Asn
825 830 835

atg gaa aat ggt aat aat ggt tat cat aaa gat cat gta tat ggt att 2599
Met Glu Asn Gly Asn Asn Gly Tyr His Lys Asp His Val Tyr Gly Ile
840 845 850

cac aat cct gtt atg aca agc cca tca caa cat tga tagctgatgt 2645
His Asn Pro Val Met Thr Ser Pro Ser Gln His
855 860 865

tgaaactgct tgagcatcag gatactcaaa gtggaaagga tcacagattt ttggtagttt 2705

ctgggtctac aaggactttc caaatccagg agcaacgcca gtggcaacgt agtgactcag 2765

gcgggcacca aggcaacggc accattggtc tctgggtagt gctttaagaa tgaacacaat 2825

cacgttatag tccatggtcc atcactattc aaggatgact ccctcccttc ctgtctattt 2885

ttgtttttta ctttttaca ctgagtttct atttagacac tacaacatat ggggtgtttg 2945

ttcccattgg atgcatttct atcaaaactc tatcaaatgt gatggctaga ttctaacata 3005

ttgccatgtg tggagtgtgc tgaacacaca ccagtttaca ggaaagatgc attttgtgta 3065

cagtaaacgg tgtatatacc ttttgttacc acagagtttt ttaaacaaat gagtattata 3125

ggactttctt ctaaatgagc taaataagtc accattgact tcttggtgct gttgaaaata 3185

atccattttc actaaaagtg tgtgaaacct acagcatatt cttcacgcag agattttcat 3245

ctattatact ttatcaaaga ttggccatgt tccacttgga aatggcatgc aaaagccatc 3305

atagagaaac ctgcgtaact ccatctgaca aattcaaaag agagagagag atcttgagag 3365

agaaatgctg ttcgttcaaa agtggagttg ttttaacaga tgccaattac ggtgtacagt 3425

ttaacagagt tttctgttgc attaggataa acattaattg gagtgcagct aacatgagta 3485

tcatcagact agtatcaagt gttctaaaat gaaatatgag aagatcctgt cacaattctt 3545

agatctggtg tccagcatgg atgaaacctt tgagtttggt ccctaaattt gcatgaaagc 3605

acaaggtaaa tattcatttg cttcaggagt ttcatgttgg atctgtcatt atcaaaagtg 3665

atcagcaatg aagaactggt cggacaaaat ttaacgttga tgtaatggaa ttccagatgt 3725

aggcattccc cccaggtctt ttcatgtgca gattgcagtt ctgattcatt tgaataaaaa 3785

ggaacttgg 3794

<210> 2

<211> 865

<212> PRT

<213> Homo sapiens

<400> 2

Met Ala Leu Val Leu Gly Ser Leu Leu Leu Leu Gly Leu Cys Gly Asn
1 5 10 15

```
Ser Phe Ser Gly Gly Gln Pro Ser Ser Thr Asp Ala Pro Lys Ala Trp
            20                  25                  30

Asn Tyr Glu Leu Pro Ala Thr Asn Tyr Glu Thr Gln Asp Ser His Lys
        35                  40                  45

Ala Gly Pro Ile Gly Ile Leu Phe Glu Leu Val His Ile Phe Leu Tyr
    50                  55                  60

Val Val Gln Pro Arg Asp Phe Pro Glu Asp Thr Leu Arg Lys Phe Leu
65                  70                  75                  80

Gln Lys Ala Tyr Glu Ser Lys Ile Asp Tyr Asp Lys Pro Glu Thr Val
                85                  90                  95

Ile Leu Gly Leu Lys Ile Val Tyr Tyr Glu Ala Gly Ile Ile Leu Cys
            100                 105                 110

Cys Val Leu Gly Leu Leu Phe Ile Ile Leu Met Pro Leu Val Gly Tyr
        115                 120                 125

Phe Phe Cys Met Cys Arg Cys Cys Asn Lys Cys Gly Gly Glu Met His
    130                 135                 140

Gln Arg Gln Lys Glu Asn Gly Pro Phe Leu Arg Lys Cys Phe Ala Ile
145                 150                 155                 160

Ser Leu Leu Val Ile Cys Ile Ile Ile Ser Ile Gly Ile Phe Tyr Gly
                165                 170                 175

Phe Val Ala Asn His Gln Val Arg Thr Arg Ile Lys Arg Ser Arg Lys
            180                 185                 190

Leu Ala Asp Ser Asn Phe Lys Asp Leu Arg Thr Leu Leu Asn Glu Thr
        195                 200                 205

Pro Glu Gln Ile Lys Tyr Ile Leu Ala Gln Tyr Asn Thr Thr Lys Asp
    210                 215                 220

Lys Ala Phe Thr Asp Leu Asn Ser Ile Asn Ser Val Leu Gly Gly Gly
225                 230                 235                 240

Ile Leu Asp Arg Leu Arg Pro Asn Ile Ile Pro Val Leu Asp Glu Ile
                245                 250                 255

Lys Ser Met Ala Thr Ala Ile Lys Glu Thr Lys Glu Ala Leu Glu Asn
            260                 265                 270

Met Asn Ser Thr Leu Lys Ser Leu His Gln Gln Ser Thr Gln Leu Ser
        275                 280                 285
```

```
Ser Ser Leu Thr Ser Val Lys Thr Ser Leu Arg Ser Ser Leu Asn Asp
    290                 295                 300

Pro Leu Cys Leu Val His Pro Ser Ser Glu Thr Cys Asn Ser Ile Arg
305                 310                 315                 320

Leu Ser Leu Ser Gln Leu Asn Ser Asn Pro Glu Leu Arg Gln Leu Pro
                325                 330                 335

Pro Val Asp Ala Glu Leu Asp Asn Val Asn Asn Val Leu Arg Thr Asp
            340                 345                 350

Leu Asp Gly Leu Val Gln Gln Gly Tyr Gln Ser Leu Asn Asp Ile Pro
        355                 360                 365

Asp Arg Val Gln Arg Gln Thr Thr Thr Val Val Ala Gly Ile Lys Arg
    370                 375                 380

Val Leu Asn Ser Ile Gly Ser Asp Ile Asp Asn Val Thr Gln Arg Leu
385                 390                 395                 400

Pro Ile Gln Asp Ile Leu Ser Ala Phe Ser Val Tyr Val Asn Asn Thr
                405                 410                 415

Glu Ser Tyr Ile His Arg Asn Leu Pro Thr Leu Glu Glu Tyr Asp Ser
            420                 425                 430

Tyr Trp Trp Leu Gly Gly Leu Val Ile Cys Ser Leu Leu Thr Leu Ile
        435                 440                 445

Val Ile Phe Tyr Tyr Leu Gly Leu Leu Cys Gly Val Cys Gly Tyr Asp
    450                 455                 460

Arg His Ala Thr Pro Thr Thr Arg Gly Cys Val Ser Asn Thr Gly Gly
465                 470                 475                 480

Val Phe Leu Met Val Gly Val Gly Leu Ser Phe Leu Phe Cys Trp Ile
                485                 490                 495

Leu Met Ile Ile Val Val Leu Thr Phe Val Phe Gly Ala Asn Val Glu
            500                 505                 510

Lys Leu Ile Cys Glu Pro Tyr Thr Ser Lys Glu Leu Phe Arg Val Leu
        515                 520                 525

Asp Thr Pro Tyr Leu Leu Asn Glu Asp Trp Glu Tyr Tyr Leu Ser Gly
    530                 535                 540

Lys Leu Phe Asn Lys Ser Lys Met Lys Leu Thr Phe Glu Gln Val Tyr
545                 550                 555                 560
```

```
Ser Asp Cys Lys Lys Asn Arg Gly Thr Tyr Gly Thr Leu His Leu Gln
                565                 570                 575

Asn Ser Phe Asn Ile Ser Glu His Leu Asn Ile Asn Glu His Thr Gly
            580                 585                 590

Ser Ile Ser Ser Glu Leu Glu Ser Leu Lys Val Asn Leu Asn Ile Phe
        595                 600                 605

Leu Leu Gly Ala Ala Gly Arg Lys Asn Leu Gln Asp Phe Ala Ala Cys
    610                 615                 620

Gly Ile Asp Arg Met Asn Tyr Asp Ser Tyr Leu Ala Gln Thr Gly Lys
625                 630                 635                 640

Ser Pro Ala Gly Val Asn Leu Leu Ser Phe Ala Tyr Asp Leu Glu Ala
                645                 650                 655

Lys Ala Asn Ser Leu Pro Pro Gly Asn Leu Arg Asn Ser Leu Lys Arg
            660                 665                 670

Asp Ala Gln Thr Ile Lys Thr Ile His Gln Gln Arg Val Leu Pro Ile
        675                 680                 685

Glu Gln Ser Leu Ser Thr Leu Tyr Gln Ser Val Lys Ile Leu Gln Arg
    690                 695                 700

Thr Gly Asn Gly Leu Leu Glu Arg Val Thr Arg Ile Leu Ala Ser Leu
705                 710                 715                 720

Asp Phe Ala Gln Asn Phe Ile Thr Asn Asn Thr Ser Ser Val Ile Ile
                725                 730                 735

Glu Glu Thr Lys Lys Tyr Gly Arg Thr Ile Ile Gly Tyr Phe Glu His
            740                 745                 750

Tyr Leu Gln Trp Ile Glu Phe Ser Ile Ser Glu Lys Val Ala Ser Cys
        755                 760                 765

Lys Pro Val Ala Thr Ala Leu Asp Thr Ala Val Asp Val Phe Leu Cys
    770                 775                 780

Ser Tyr Ile Ile Asp Pro Leu Asn Leu Phe Trp Phe Gly Ile Gly Lys
785                 790                 795                 800

Ala Thr Val Phe Leu Leu Pro Ala Leu Ile Phe Ala Val Lys Leu Ala
                805                 810                 815

Lys Tyr Tyr Arg Arg Met Asp Ser Glu Asp Val Tyr Asp Asp Val Glu
            820                 825                 830
```

Thr Ile Pro Met Lys Asn Met Glu Asn Gly Asn Asn Gly Tyr His Lys
835 840 845

Asp His Val Tyr Gly Ile His Asn Pro Val Met Thr Ser Pro Ser Gln
850 855 860

His
865